 CytoDyn Inc. OTCQB:CYDY, a late-stage biotechnology company developing its flagship drug leronlimab for multiple indications, revealed that it has initiated the resubmission of its Biologics License Application BLA for HIV human immunodeficiency virus under rolling review consistent with guidance from the US Food and Drug Administration FDA. In a statement, CytoDyn CEO Nader Pourhassan said: We are pleased to begin the HIV BLA resubmission process with continued guidance from the FDA. 